Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

POSITIVE PROFIT ALERT

This announcement is made by Medtide Inc. (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary review of the unaudited management accounts of the Group for the year ended December 31, 2025 and information currently available, it is expected that (i) the revenue of Group for the year ended December 31, 2025 will be within the range of approximately RMB555 million to RMB585 million, representing an increase of approximately 25.5% to 32.3%, as compared to the revenue for the year ended December 31, 2024 of approximately RMB442.2 million; (ii) the profit of the Group for the year ended December 31, 2025 will be within the range of approximately RMB200 million to RMB230 million, representing an increase of approximately 237.8% to 288.5%, as compared to the profit for the year ended December 31, 2024 of approximately RMB59.2 million; and (iii) the adjusted net profit of the Group, which is a non-IFRS measure, for the year ended December 31, 2025 will be within the range of approximately RMB200 million to RMB230 million, representing an increase of approximately 16.3% to 33.7%, as compared to the adjusted net profit for the year ended December 31, 2024 of approximately RMB172.0 million.

Based on the information currently available to the Board, the Board believes that:

(a) the increase in revenue was primarily due to (i) the successful execution of the "going with compound" strategy, along with the strengths of the Group's integrated contract research, development and manufacturing organization (CRDMO) platform, industry-leading project delivery timelines, and proven track record of excellent project execution, and (ii) strong demand for our services from key customers continues to grow, driven by the development of their pipelines and the rapid expansion of the global peptide market, particularly in the glucagon like peptide-1 (GLP-1) sector;

(b) the increase in profit was primarily due to the combined effects of (i) the above mentioned revenue growth; (ii) the cost savings and efficiency improvements through the optimization of the Group's operational management system; and (iii) the fair value gain on financial liabilities at fair value through profit or loss ("**FVTPL**") recognized for the year ended December 31, 2025, due to the redemption liabilities being converted into equity upon the listing of H shares of Company on the Stock Exchange (the "**Listing**"), compared with a fair value loss for the year ended December 31, 2024 (please refer to the interim results announcement of the Company dated August 29, 2025 and the prospectus of the Company dated June 20, 2025 for more details); and

(c) the increase in adjusted net profit was primarily due to the combined effects of (i) the above mentioned revenue growth, and (ii) the cost savings and efficiency improvements through the optimization of the Group's operational management system.

The Board wishes to highlight that "adjusted net profit" is not defined under the International Financial Reporting Standards ("**IFRS**"). It is defined by the Group as profit for the year adjusted by adding back (i) fair value gains or losses on financial liabilities at FVTPL comprising fair value gains or losses on convertible bonds and redemption liabilities, of which the redemption liabilities converted into equity upon the Listing, (ii) share-based payment compensation, which are non-cash in nature, and (iii) listing expenses. The management of the Company believes that the presentation of such non-IFRS measure when shown in conjunction with the corresponding IFRS measures provides useful information to investors and management in facilitating a comparison of our operating performance from period to period by eliminating potential impacts of certain non-operational or non-recurring expenses that do not affect the ongoing operating performance of the Company. Such non-IFRS measure allows investors to consider metrics used by our management in evaluating our performance.

The use of the non-IFRS measure has limitations as an analytical tool, and Shareholders and potential investors of the Company should not consider it in isolation from, or as a substitute for or superior to analysis of, our results of operations or financial condition as reported under IFRS. In addition, such non-IFRS measure may be defined differently from similar terms used by other companies and therefore may not be comparable to similar measures presented by other companies.

The Board would like to remind that, as of the date of this announcement, the Company is still in the process of finalising the annual results announcement of the Group for the year ended December 31, 2025. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 and information currently available to the Board, and is not based on any figures or information which have been reviewed or confirmed by the audit committee of the Board, or reviewed or audited by the auditors of the Company. The actual results of the Group for the year ended December 31, 2025 may differ from those disclosed in this announcement. They shall not be taken as a measure or indication of the Group's current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Company's annual results announcement for the year ended December 31, 2025, which is expected to be published by the end of March 2026 in accordance with the requirements of the Listing Rules. As such, the above figures are provided for Shareholders' and investors' reference only. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the year ended December 31, 2025.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors are advised to seek professional advice from professional or financial advisers.

By order of the Board
Medtide Inc.
Dr. Xu Qi
Chairwoman and Chief Executive Officer

Hong Kong, February 26, 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).